RecruitingNCT06849063

Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE

3D-MRE-Based Evaluation of Biomechanical Heterogeneity in Pancreatic Cancer and Its Clinical Prognosis

Sponsor

Yu Shi

Enrollment

200 participants

Start Date

Oct 9, 2020

Study Type

OBSERVATIONAL

Conditions

Pancreatic Cancer

Summary

Pancreatic ductal adenocarcinoma (PDAC), representing 85-95% of pancreatic cancers, is a highly lethal malignancy with a dismal 5-year survival rate below 8%. Emerging evidence highlights the critical need for non-invasive imaging biomarkers to stratify prognosis and guide therapeutic strategies. Notably, the biomechanical properties of PDAC-associated extracellular matrix (ECM), characterized by extensive interstitial fibrosis, are intrinsically linked to tumorigenesis, progression, and metastatic dissemination. Three-dimensional magnetic resonance elastography (3D-MRE), as an advanced imaging modality, enables precise quantification of tissue shear stiffness in both normal pancreatic parenchyma and neoplastic lesions. Significantly, the biomechanical heterogeneity captured by MRE holds untapped potential to serve as a prognostic biomarker for PDAC. Despite its technical merits, no studies to date have systematically explored MRE-derived imaging signatures in predicting PDAC survival outcomes or therapeutic responses, underscoring a pivotal gap in translational oncology research.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether a special type of MRI called 3D magnetic resonance elastography (3D MRE) — which measures the stiffness of tissue — can predict how well patients with pancreatic cancer will do after surgery. Stiffer tumors may behave differently than softer ones. **You may be eligible if...** - You are 18 years of age or older - You have been confirmed by biopsy to have pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - You have not had bile duct drainage before surgery - You have no history of cancer in other parts of the body - You are scheduled for surgical removal of the tumor and have been followed up for at least 3–6 months afterward **You may NOT be eligible if...** - You have had prior cancer in another location - You had preoperative biliary drainage - You are unable to undergo MRI (e.g., metal implants, claustrophobia) - You have not provided written consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.